Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Nephrology  |  Oncology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Renal Cell Carcinoma Clinical Trials

A listing of Renal Cell Carcinoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found (133) clinical trials

Study With Andes-1537 in Patients With Specific Types of Advanced Solid Tumor

After screening, 9 patients in each cancer type-specific cohort (gallbladder & biliary tract carcinoma; cervical carcinoma; colorectal carcinoma; gastric carcinoma; pancreatic carcinoma; and clear cell renal cancer) will enter stage 1. These patients will receive a dose of 400 mg of Andes-1537 twice a week (BIW) for continuous cycles of …


A Trial of PT2977 in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC)

This is an open-label Phase 2 study which will evaluate the efficacy and safety of PT2977 in combination with cabozantinib in patients with advanced ccRCC. PT2977 will be administered orally and cabozantinib will be administered orally once daily.


LITT and Pembrolizumab in Recurrent Brain Metastasis

Adult patients with a primary cancer approved by the FDA for treatment with an immune-checkpoint inhibitor who have recurrent brain metastasis that have failed stereotactic radiosurgery treatment will be screened. They will sign consent and complete screening procedures. Each patient will be scheduled to undergo biopsy and LITT treatment. Within …


Study of SRF388 in Patients With Advanced Solid Tumors

This is a Phase 1, open-label, first-in-human (FIH), dose-escalation monotherapy, safety, and expansion study of SRF388, a monoclonal antibody targeting IL-27, that will be conducted in 3 parts Part A: SRF388 monotherapy dose-escalation cohort in patients with advanced solid tumors. Part B: SRF388 monotherapy clear cell renal cell carcinoma (ccRCC) …


Study of ADCT-301 in Patients With Selected Advanced Solid Tumors

This is a Phase 1b, multi-center, open-label study with a dose-escalation part and a dose expansion part. The duration of the study participation for each patient is defined as the time from the date of signed written informed consent to the completion of the follow-up period, withdrawal of consent, loss …


Study of INBRX-105 in Patients With Solid Tumors

This is a first-in-human, open-label, nonrandomized, two-part Phase 1 trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX-105. INBRX-105, a next generation bispecific antibody, targets the human programmed death-ligand 1 (PD-L1) receptor and the human 4-1BB receptor. INBRX-105 …


RFR Change of Precise Segmental Versus Complete Renal Arterial Clamping During LPN for Clinical T1 RCC

Renal functional reserve (RFR) describes the capacity of the intact nephron mass to increase glomerular filtration rate(GFR) from baseline in response to stimuli (e.g., protein load).We hypothesized that renal functional reserve may be better in patients with clinical T1 renal cell carcinoma(RCC) undergoing laparoscopic partial(LPN) nephrectomy with precise segmental renal …

Phase N/A

A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma

The purpose of this study is to compare any good and bad effects of using a combination of nivolumab (Opdivo) and cabozantinib (Cabometyx) in people with metastatic kidney cancer.


Talazoparib and Axitinib for People With Previously Treated Advanced Kidney Cancer

Researchers are doing this study to find out if the combination of the drugs axitinib and talazoparib is a safe and effective treatment for people with your previously treated advanced kidney cancer. Researchers will look for the highest dose of talazoparib that causes few or mild side effects when given …


A Study of XmAb 22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors

This is a Phase 1, multiple dose, ascending-dose escalation study and expansion study designed to define a maximum tolerated dose and/or recommended dose of XmAb22841 monotherapy and in combination with pembrolizumab; to assess safety, tolerability, pharmacokinetics, immunogenicity, and anti-tumor activity of XmAb22841 monotherapy and in combination with pembrolizumab in subjects …